Waters Corporation to Present at J.P. Morgan Healthcare Conference on January 12, 2026
- Waters Corporation will present at the J.P. Morgan Healthcare Conference on January 12, 2026, at 2:15 PM PT.
- The presentation will be streamed live and available for replay on Waters' Investor Relations website for 90 days.
- Waters emphasizes its commitment to innovation in healthcare solutions, enhancing product quality, and addressing customer needs.
Waters Corporation Prepares for Key Presentation at J.P. Morgan Healthcare Conference
Waters Corporation, a prominent player in analytical instruments and separations technologies, gears up for an important presentation at the 44th Annual J.P. Morgan Healthcare Conference. Udit Batra, Ph.D., the company’s President and CEO, is set to present on January 12, 2026, at 2:15 PM Pacific Time. This high-profile event is a key platform for industry leaders to discuss advancements and trends in healthcare, and Waters’ participation signals its commitment to engaging with stakeholders on critical issues affecting life sciences and analytical applications. The presentation will be accessible via a live webcast on the Waters Investor Relations website, with a replay option available for 90 days post-event, ensuring a wide reach for interested audiences.
Waters Corporation has built a reputation over its 65-plus years of operation as a leader in providing solutions that enhance the efficacy of medicines, ensure food safety, and maintain water purity. The company’s innovative technologies serve a variety of sectors, including life sciences, materials science, and environmental analysis. By addressing the specific needs of its customers in laboratories, manufacturing sites, and hospitals, Waters helps to drive advancements in scientific research and product quality, positioning itself as a crucial partner in the healthcare ecosystem. The expertise and dedication of its 7,600 employees across more than 100 countries enable Waters to effectively tackle the challenges faced by its diverse clientele.
As health and safety become increasingly paramount in global markets, Waters Corporation remains committed to pioneering science and innovation. The upcoming presentation at the J.P. Morgan Healthcare Conference is expected to highlight the company's strategic initiatives and partnerships aimed at enhancing healthcare solutions. By actively participating in industry dialogues, Waters demonstrates its dedication to addressing the evolving needs of its customers and contributing to global health advancements.
In addition to the conference presentation, those interested in Waters’ corporate developments can reach out to Caspar Tudor, the Head of Investor Relations, for more information. The company's ongoing focus on innovation and customer collaboration underscores its mission to support the advancement of scientific research and improve the quality of everyday products.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

